**Key word(s): China restructuring; revised outlook**

**Ad hoc Announcement according to Art. 17 Market Abuse Regulation**

**QIAGEN’s Q2 2019 results in line with CER outlook, revised 2019 outlook due to intended restructuring of China NGS partnership**

**Venlo, The Netherlands, July 24, 2019 –** QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces that it achieved the outlook set for net sales growth and adjusted earnings per share at constant exchange rates (CER) for the second quarter of 2019.

As a result of the intention to restructure its next-generation sequencing (NGS) partnership in China, QIAGEN now expects full-year 2019 net sales growth of approximately 5-6% CER (previously about 7-8% CER) and adjusted diluted EPS of approximately $1.42-1.44 CER per share (previously about $1.45-1.47 CER). For the third quarter of 2019, QIAGEN expects net sales to grow approximately 4-5% CER. Adjusted diluted EPS is expected to be about $0.35-0.36 CER per share.

QIAGEN intends to restructure the current format of its NGS partnership in China due to the slower-than-expected uptake of invitro diagnostic clinical sequencing in this country. Sales from this partnership were planned to be approximately $30 million for full-year 2019, and weighted primarily to the second half of this year.

QIAGEN N.V.

Hulsterweg 82

5912 PL Venlo

The Netherlands

ISIN: NL0012169213

Frankfurt Stock Exchange, Regulated Market (Prime Standard)

Contacts QIAGEN N.V.:

Corporate Communications

John Gilardi, Tel: +49 2103 29 11711; [ir@qiagen.com](mailto:ir@qiagen.com)

Thomas Theuringer, Tel: +49 2013 29 11826 [pr@qiagen.com](mailto:pr@qiagen.com)